Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, has announced the approval from FDA for the designation of Revusiran.
Revusiran is a therapeutic drug for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
View the full release here.